Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Gastroesophageal Cancer”

82 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 82 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05480384
What this trial is testing

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Who this might be right for
Esophageal AdenocarcinomaEsophageal CancerHER-2 Protein Overexpression+1 more
Brown University 1
Not applicableStudy completedNCT04920747
What this trial is testing

Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients

Who this might be right for
HER2-positive Gastric CancerMetastatic CancerDocetaxel+1 more
Centre Hospitalier Universitaire de Besancon 65
Testing effectiveness (Phase 2)Ended earlyNCT05555251
What this trial is testing

BI-1607 in Combination with Trastuzumab in Subjects with HER2-positive Advanced Solid Tumors

Who this might be right for
HER2-positive Breast CancerHER2-positive Gastric CancerHER2-positive Metastatic Breast Cancer+2 more
BioInvent International AB 18
Early research (Phase 1)UnknownNCT05315830
What this trial is testing

HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric

Who this might be right for
Adenocarcinoma - GEJAdenocarcinoma of the Stomach
The First Affiliated Hospital of Bengbu Medical University 10
Early research (Phase 1)Study completedNCT03821233
What this trial is testing

A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers

Who this might be right for
HER2-expressing Cancers
Zymeworks BC Inc. 112
Testing effectiveness (Phase 2)Ended earlyNCT02726399
What this trial is testing

Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Memorial Sloan Kettering Cancer Center 7
Early research (Phase 1)WithdrawnNCT04602117
What this trial is testing

ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer

Who this might be right for
HER2-positive Breast CancerHER2 LowSYD-985+24 more
QuantumLeap Healthcare Collaborative
Large-scale testing (Phase 3)Looking for participantsNCT06532006
What this trial is testing

A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Who this might be right for
Gastroesophageal-junction CancerMonoclonal AntibodyGastric Cancer+1 more
Shanghai Henlius Biotech 550
Early research (Phase 1)Ended earlyNCT01705340
What this trial is testing

Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery

Who this might be right for
Adenocarcinoma of the Gastroesophageal JunctionHER2-positive Breast CancerMale Breast Cancer+9 more
National Cancer Institute (NCI) 60
Large-scale testing (Phase 3)Study completedNCT01774786
What this trial is testing

Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 780
Testing effectiveness (Phase 2)Active Not RecruitingNCT05190445
What this trial is testing

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Who this might be right for
HER2-positive Gastric Cancer
Pieris Pharmaceuticals, Inc. 80
Testing effectiveness (Phase 2)Looking for participantsNCT06253650
What this trial is testing

Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease

Who this might be right for
Gastric CancerHER2-positive Gastric Cancer
Gruppo Oncologico del Nord-Ovest 46
Large-scale testing (Phase 3)Looking for participantsNCT06731478
What this trial is testing

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

Who this might be right for
Gastric CancerGastroesophageal Junction Cancer
Daiichi Sankyo 726
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 243
Large-scale testing (Phase 3)Ended earlyNCT01641939
What this trial is testing

Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer

Who this might be right for
Gastric Cancer
Hoffmann-La Roche 415
Large-scale testing (Phase 3)Looking for participantsNCT06901531
What this trial is testing

Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer

Who this might be right for
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or CancerLocally Advanced Unresectable Gastric Adenocarcinoma or CancerMetastatic Gastric Adenocarcinoma or Cancer+1 more
Astellas Pharma Global Development, Inc.
Testing effectiveness (Phase 2)Looking for participantsNCT06157892
What this trial is testing

Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Who this might be right for
Breast NeoplasmsGastroesophageal Junction AdenocarcinomaHER2 Low Breast Neoplasms+7 more
Seagen, a wholly owned subsidiary of Pfizer 172
Testing effectiveness (Phase 2)UnknownNCT05619016
What this trial is testing

[68Ga]Ga-ABY-025 PET for Quantification of HER2-status in Solid Tumors

Who this might be right for
Esophageal NeoplasmsGastric Neoplasms MalignantBreast Cancer+1 more
Karolinska University Hospital 72
Not applicableStudy completedNCT05892926
What this trial is testing

HER2-positive Locally Advanced/Metastatic Gastric and/or Gastroesophageal Junction (GEJ) Adenocarcinoma in Russia

Who this might be right for
Adenocarcinoma
AstraZeneca 204
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06439550
What this trial is testing

Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 42
Load More Results
500